Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| AstraZeneca | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study investigates the common features of electrophysiological measures in schizophrenia and effects of NMDA antagonist ketamine in healthy volunteers.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| healthy control | Experimental | Healthy controls will receive electrophysiological assessments before and after NMDA antagonist administration. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ketamine | Drug | For healthy volunteer arm of study, NMDA antagonist ketamine will be administered. 0.23 mg/kg over 1 minute, followed by 0.58 mg/kg/hour for 30 minutes, followed by 0.29 mg/kg/hour for 50 minutes. No drug administration for patients with schizophrenia |
| Measure | Description | Time Frame |
|---|---|---|
| P300, an ERP measure | Baseline and repeat assessment following ketamine |
| Measure | Description | Time Frame |
|---|---|---|
| (Mismatch Negativity) MMN | Baseline and repeat assessment |
Not provided
Subjects for the Ketamine experiment(Healthy control experiment):
Inclusion Criteria:
Exclusion Criteria:
Subjects for the Schizophrenia experiment:
Inclusion Criteria for control subjects:
Exclusion Criteria for control subjects:
Inclusion Criteria for patients:
Exclusion Criteria:
Lifetime diagnosis of DSM-IV substance dependence (except caffeine and nicotine).
Substance abuse, as per clinical judgment, in the past 1 year
A history of significant medical/neurological disease such as cardiac, thyroid, renal, hepatic or neurological.
A hearing deficit greater than 30dB in both ears detected using a Welch-Allyn audioscope (500, 1000, 2000 and 4000 Hz threshold will be evaluated) at screening.
History of head injury with loss of consciousness greater than fifteen minutes.
Any other condition or medication, which in the opinion of the investigator would preclude participation in the study.
Non-English speaking.
-
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Handan Gunduz-Bruce, M.D. | Yale Medical School | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| VHA CT | West Haven | Connecticut | 06516 | United States |
Not provided
| ID | Term |
|---|---|
| D012559 | Schizophrenia |
| ID | Term |
|---|---|
| D019967 | Schizophrenia Spectrum and Other Psychotic Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D007649 | Ketamine |
| ID | Term |
|---|---|
| D003510 | Cyclohexanes |
| D003516 | Cycloparaffins |
| D006840 | Hydrocarbons, Alicyclic |
| D006844 | Hydrocarbons, Cyclic |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| D006838 |
| Hydrocarbons |
| D009930 | Organic Chemicals |